日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Discovery of Potent and Selective MTH1 Inhibitors for Oncology: Enabling Rapid Target (In)Validation

发现用于肿瘤治疗的高效选择性MTH1抑制剂:实现靶点(不)验证的快速开展

Farand, Julie; Kropf, Jeffrey E; Blomgren, Peter; Xu, Jianjun; Schmitt, Aaron C; Newby, Zachary E; Wang, Ting; Murakami, Eisuke; Barauskas, Ona; Sudhamsu, Jawahar; Feng, Joy Y; Niedziela-Majka, Anita; Schultz, Brian E; Schwartz, Karen; Viatchenko-Karpinski, Serge; Kornyeyev, Dmytro; Kashishian, Adam; Fan, Peidong; Chen, Xiaowu; Lansdon, Eric B; Ports, Michael O; Currie, Kevin S; Watkins, William J; Notte, Gregory T

Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis

Btk特异性抑制可阻断IFNα驱动的狼疮性肾炎中的致病性浆细胞特征和髓系细胞相关损伤

Katewa, Arna; Wang, Yugang; Hackney, Jason A; Huang, Tao; Suto, Eric; Ramamoorthi, Nandhini; Austin, Cary D; Bremer, Meire; Chen, Jacob Zhi; Crawford, James J; Currie, Kevin S; Blomgren, Peter; DeVoss, Jason; DiPaolo, Julie A; Hau, Jonathan; Johnson, Adam; Lesch, Justin; DeForge, Laura E; Lin, Zhonghua; Liimatta, Marya; Lubach, Joseph W; McVay, Sami; Modrusan, Zora; Nguyen, Allen; Poon, Chungkee; Wang, Jianyong; Liu, Lichuan; Lee, Wyne P; Wong, Harvey; Young, Wendy B; Townsend, Michael J; Reif, Karin

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

将 Idelalisib 与新型脾酪氨酸激酶 (Syk) 抑制剂 GS-9973 联合使用,有望成为治疗慢性淋巴细胞白血病的潜在疗法

Burke Russell T, Meadows Sarah, Loriaux Marc M, Currie Kevin S, Mitchell Scott A, Maciejewski Patricia, Clarke Astrid S, Dipaolo Julie A, Druker Brian J, Lannutti Brian J, Spurgeon Stephen E